Q1 sales were in line, driven by the resilience of the speciality care portfolio (comprises drugs for critical conditions). The COVID-19 impact was limited as increased stocking of oncology drugs in Europe offset the weakness in China. While Q2 could be slow, due to delayed diagnoses and fewer new patient starts, the mid-term growth prospects are improving – limited impact of generics on Somatuline and encouraging clinical results for Cabometyx. Revival of palovarotene is also a positiv
23 Apr 2020
In line Q1; while Q2 could be slow, mid-term prospects improving
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
In line Q1; while Q2 could be slow, mid-term prospects improving
Ipsen SA (IPN:WBO) | 0 0 5.0% | Mkt Cap: 10,144m
- Published:
23 Apr 2020 -
Author:
Sumit Sayal -
Pages:
4
Q1 sales were in line, driven by the resilience of the speciality care portfolio (comprises drugs for critical conditions). The COVID-19 impact was limited as increased stocking of oncology drugs in Europe offset the weakness in China. While Q2 could be slow, due to delayed diagnoses and fewer new patient starts, the mid-term growth prospects are improving – limited impact of generics on Somatuline and encouraging clinical results for Cabometyx. Revival of palovarotene is also a positiv